Get the Stockscreener App
0.8962
6.31%
-0.0604
After Hours:
.88
-0.0162
-1.81%
Context Therapeutics Inc stock is traded at $0.8962, with a volume of 106.70K.
It is down -6.31% in the last 24 hours and down -23.40% over the past month.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
See More
Previous Close:
$0.9566
Open:
$0.9815
24h Volume:
106.70K
Relative Volume:
0.23
Market Cap:
$67.21M
Revenue:
-
Net Income/Loss:
$-30.15M
P/E Ratio:
-0.9848
EPS:
-0.91
Net Cash Flow:
$-31.63M
1W Performance:
-6.28%
1M Performance:
-23.40%
6M Performance:
-61.20%
1Y Performance:
-12.14%
1-Day Range:
$0.877
$0.9815
1-Week Range:
$0.8547
$0.9815
52-Week Range:
$0.7936
$2.75
Context Therapeutics Inc Stock (CNTX) Company Profile
Name
Context Therapeutics Inc
Sector
Industry
Phone
267-225-7416
Address
2001 MARKET STREET, PHILADELPHIA
Compare CNTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
0.8962 | 67.21M | 0 | -30.15M | -31.63M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-25 | Initiated | JMP Securities | Mkt Outperform |
| Nov-25-24 | Initiated | D. Boral Capital | Buy |
| May-16-24 | Initiated | Piper Sandler | Overweight |
Context Therapeutics Inc Stock (CNTX) Latest News
Analysts Set Context Therapeutics Inc. (NASDAQ:CNTX) PT at $6.33 - Defense World
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Context Therapeutics Stock Jumps Pre-Market On Analyst's Near 4x Upside View: Retail Pins High Hopes Too - MSN
Franklin Resources Inc. Acquires Additional Shares in Context Th - GuruFocus.com
Context Therapeutics Welcomes Andy Pasternak as New Chairman of the Board - MSN
Breakthrough in Cancer Treatment? Context Therapeutics Launches Phase 1 Trial for CLDN6-Targeted Therapy - MSN
Context Therapeutics Inc. (NASDAQ:CNTX) Short Interest Update - MarketBeat
Context Therapeutics’ (CNTX) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Context doses first subject in Phase I cancer trial of CTIM-76 - Yahoo Finance
Context Therapeutics (NASDAQ:CNTX) Receives Buy Rating from D. Boral Capital - MarketBeat
Context Therapeutics Advances CTIM-76 in Clinical Pipeline - TipRanks
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76 - GlobeNewswire
Context Therapeutics Launches Phase 1 Trial for Novel Cancer Treatment CTIM-76 - StockTitan
Context Therapeutics Appoints Andy Pasternak as Chairman - TipRanks
Context Therapeutics appoints new chairman Andy Pasternak - Investing.com India
Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors - The Manila Times
Context Therapeutics Names Former Horizon Executive Andy Pasternak as Board Chairman - StockTitan
Pre-market Movers: AVGR, TIVC, ATNF, SLGL... - RTTNews
Context Therapeutics Inc. (NASDAQ:CNTX) Receives $6.80 Average Target Price from Brokerages - Defense World
Geode Capital Management LLC Cuts Stock Holdings in Context Therapeutics Inc. (NASDAQ:CNTX) - Defense World
Geode Capital Management LLC Purchases 70,070 Shares of DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World
JMP Securities Begins Coverage on Context Therapeutics (NASDAQ:CNTX) - Defense World
Context Therapeutics (NASDAQ:CNTX) Raised to Strong-Buy at Citizens Jmp - Defense World
MPM BIOIMPACT LLC Acquires Significant Stake in Context Therapeu - GuruFocus.com
Context Therapeutics (NASDAQ:CNTX) Stock Rating Upgraded by Citizens Jmp - MarketBeat
SpringWorks Therapeutics Stock Gets A RS Rating Lift - MSN
Aclaris Therapeutics Awards Stock Options to Attract Top Talent - MSN
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Context Therapeutics (NASDAQ:CNTX) Earns Outperform Rating from Analysts at JMP Securities - MarketBeat
Pre-market Movers: SANA, SLDB, JSPR, DRIO... - RTTNews
This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Analyst sees upside in Context Therapeutics stock—next-gen antibodies in spotlight - Investing.com Nigeria
Pre-market Movers: CDT, NARI, GDTC, NARI... - RTTNews
Philly’s year in biopharma: a look back at 2024 - MSN
State Street Corp Purchases 19,800 Shares of Context Therapeutics Inc. (NASDAQ:CNTX) - Defense World
Cal-Maine Foods IN (CALM-Q) QuotePress Release - The Globe and Mail
APLT INVESTOR NOTICE: Applied Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - The Malaysian Reserve
Short Interest in Context Therapeutics Inc. (NASDAQ:CNTX) Expands By 22.9% - MarketBeat
Context Therapeutics Inc Stock (CNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):